B6E.F Swedish Orphan Biovitrum AB (publ)
- Market cap
- EUR 15.2B
- P/E
- 24.9x
- P/B
- 3.71x
- ROE
- 14.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is B6E.F undervalued?
Graham numberB6E.F trades 102.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Swedish Orphan Biovitrum AB (publ) fundamental analysis
No fundamental analysis for Swedish Orphan Biovitrum AB (publ) yet.
Swedish Orphan Biovitrum AB (publ) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Swedish Orphan Biovitrum AB (publ)
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal no…
Full company profileSwedish Orphan Biovitrum AB (publ) financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Swedish Orphan Biovitrum AB (publ) annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 5.20B | 6.51B | 9.14B | 14.2B | 15.3B | 15.5B | 18.8B | 22.1B | 26.0B | 28.2B | 32.2B |
| Gross Profit | 3.65B | 4.66B | 6.72B | 10.9B | 12.0B | 12.0B | 14.0B | 17.1B | 20.2B | 22.0B | 24.8B |
| Operating Income | 1.10B | 1.65B | 3.12B | 4.50B | 4.46B | 3.79B | 3.85B | 4.18B | 5.62B | 922M | 9.55B |
| EBITDA | - | 2.08B | 3.62B | 6.08B | 6.69B | 5.72B | 6.20B | 7.27B | 9.33B | 10.9B | 13.3B |
| Net Income | 809M | 1.15B | 2.42B | 3.30B | 3.25B | 2.68B | 2.64B | 2.41B | 3.89B | 478M | 6.35B |
| EPS | - | 4.27 | 8.96 | 11 | 11 | 9.08 | 8.91 | 7.09 | 11 | 1.38 | 18 |
| Balance Sheet | |||||||||||
| Total Assets | 9.97B | 10.9B | 17.2B | 45.7B | 48.3B | 48.7B | 52.5B | 74.0B | 75.4B | 67.4B | 85.5B |
| Total Liabilities | 4.62B | 4.20B | 8.14B | 28.7B | 28.1B | 25.5B | 26.0B | 40.2B | 35.1B | 29.7B | 40.1B |
| Shareholders' Equity | 5.35B | 6.70B | 9.04B | 16.9B | 20.2B | 23.2B | 26.5B | 33.9B | 40.3B | 37.7B | 45.4B |
| Cash & Short-term Investments | 786M | 1.48B | 3.00B | 737M | 404M | 1.05B | 1.36B | 904M | 1.14B | 1.04B | 1.01B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 343M | 1.33B | 2.09B | 3.63B | 4.93B | 5.47B | 4.67B | 4.47B | 7.39B | 8.57B | 6.55B |
| Capital Expenditure | 164M | 47.5M | 41.0M | 37.0M | 41.0M | 47.0M | 72.0M | 4.94B | 3.01B | 3.15B | 1.80B |
| Free Cash Flow | - | 1.19B | 1.51B | -6.11B | 1.36B | 5.10B | 3.19B | -473M | 4.38B | 5.41B | 4.75B |
| Ratios | |||||||||||
| ROE | 15.1% | 17.1% | 26.7% | 19.5% | 16.1% | 11.5% | 9.9% | 7.1% | 9.6% | 1.3% | 14.0% |
| ROA | 8.1% | 10.5% | 14.1% | 7.2% | 6.7% | 5.5% | 5.0% | 3.3% | 5.1% | 0.7% | 7.4% |
| Net Profit Margin | 15.5% | 17.6% | 26.5% | 23.2% | 21.3% | 17.3% | 14.0% | 10.9% | 14.9% | 1.7% | 19.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Swedish Orphan Biovitrum AB (publ) dividends
Swedish Orphan Biovitrum AB (publ) has not paid dividends in the last 9 fiscal years.
Who owns Swedish Orphan Biovitrum AB (publ)
- Insiders 10.09%
- Institutions 70.07%
- Public & others 19.84%
- Shares outstanding 348M
- Free float 347M
Swedish Orphan Biovitrum AB (publ) company profile
- Company name
- Swedish Orphan Biovitrum AB (publ)
- Ticker
- B6E.F
- ISIN
- SE0000872095
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 2,207
- Fiscal year end
- December
- Address
- Norra Stationsgatan 93A, Stockholm, Sweden
- Phone
- 46 86 97 20 00
- Website
- sobi.com
About Swedish Orphan Biovitrum AB (publ)
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemophagocytic lymphohistiocytosis; Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis; Orfadin for hereditary tyrosinemia type 1 and alkaptonuria; Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children; VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis; and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma. The company also provides other medicines, such as Akynzeo, Jyseleca, Tegsedi, and Waylivra, as well as develops drug substances for ReFacto AF/Xyntha for Pfizer. The company has collaboration agreements with Sanofi, Apellis Pharmaceuticals, Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. The company is in strategic partnership with Innate Pharma SA to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma. The company was incorporated in 1939 and is headquartered in Stockholm, Sweden.
Swedish Orphan Biovitrum AB (publ) management
10- Dr. Guido Oelkers Ph.D.CEO & President · born 1965
- Mr. Henrik Stenqvist M.Sc.Chief Financial Officer · born 1967
- Gerard TobinHead of Investor Relations
- Mr. Torbjörn HallbergGeneral Counsel & Head of Legal Affairs · born 1969
- Ms. Lena BjurnerHead of People & Communication · born 1968
- Mr. Norbert OppitzHead of International · born 1967
- Mr. Sofiane FahmyHead of Europe · born 1972
- Mr. Duane H. BarnesHead of North America · born 1960
- Mr. Daniel RankinChief Business Officer · born 1980
- Mr. Mahmood LadhaHead of Strategic Transformation Operations · born 1964